Everolimus efficacy across adult age ranges


  • Everolimus (EVE) as an add-on therapy mitigates seizure frequency for individuals with tuberous sclerosis complex (TSC) epilepsy, with no reduction in efficacy due to a person’s age.

Why this matters

    While preclinical data indicates the effectiveness of EVE in treating TSC epilepsy may vary by age, there is a lack of published data about EVE on older adults in a clinical setting.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.